Steven Cook Sells 6,800 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 6,800 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $17.23, for a total value of $117,164.00. Following the completion of the transaction, the chief financial officer directly owned 187,209 shares of the company’s stock, valued at approximately $3,225,611.07. The trade was a 3.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Omada Health Trading Down 1.4%

OMDA traded down $0.24 on Tuesday, reaching $17.09. The stock had a trading volume of 729,778 shares, compared to its average volume of 1,213,043. The company has a market capitalization of $1.02 billion and a price-to-earnings ratio of -63.30. The firm has a 50-day moving average of $15.45 and a 200-day moving average of $14.80. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03. The company had revenue of $78.05 million during the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. Sell-side analysts anticipate that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on OMDA. The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a research note on Friday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Omada Health in a research note on Friday, May 8th. Citizens Jmp upped their target price on Omada Health from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Friday, May 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Omada Health in a research report on Thursday, June 4th. Finally, JPMorgan Chase & Co. cut their target price on Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.91.

Institutional Investors Weigh In On Omada Health

Several institutional investors and hedge funds have recently made changes to their positions in OMDA. BIT Capital GmbH bought a new position in Omada Health in the third quarter worth approximately $13,639,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Omada Health in the fourth quarter worth approximately $1,222,000. Divisadero Street Capital Management LP bought a new position in Omada Health in the third quarter worth approximately $30,510,000. a16z Perennial Management L.P. bought a new position in Omada Health in the fourth quarter worth approximately $2,480,000. Finally, Madryn Asset Management LP bought a new position in Omada Health in the fourth quarter worth approximately $9,212,000.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.